Which has stronger earnings & valuation, PBLS or IMTX?

Parabilis Medicines has higher earnings, but lower revenue than Immatics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A Immatics $54.60M 21.58 -$222.26M -$1.86 N/A

Does the media prefer PBLS or IMTX?

In the previous week, Parabilis Medicines had 4 more articles in the media than Immatics. MarketBeat recorded 5 mentions for Parabilis Medicines and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Parabilis Medicines' score of 0.58 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EWTX or IMTX?

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Edgewise Therapeutics' score of 0.75 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IMTX or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for Immatics. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Immatics' score of 1.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMTX or CELC more profitable?

Celcuity has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Immatics -495.71% -47.41% -39.45% Celcuity N/A -350.78% -41.54%

Does the media refer more to IMTX or CELC?

In the previous week, Celcuity had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Celcuity and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Celcuity's score of 0.83 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or IMTX?

In the previous week, Enliven Therapeutics had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Enliven Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Enliven Therapeutics' score of 0.54 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immatics (IMTX) Competitors

$8.62 -0.20 (-2.27%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.52 -0.10 (-1.16%)

As of 09/18/2026 07:30 PM Eastern

Compare

IMTX vs. PBLS, EWTX, ACAD, CELC, and ELVN

Should you buy Immatics stock or one of its competitors? Immatics's main competitors and comparable companies include Parabilis Medicines (PBLS), Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), and Enliven Therapeutics (ELVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immatics compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Parabilis Medicines has higher earnings, but lower revenue than Immatics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A

In the previous week, Parabilis Medicines had 4 more articles in the media than Immatics. MarketBeat recorded 5 mentions for Parabilis Medicines and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Parabilis Medicines' score of 0.58 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential downside of 0.15%. Immatics has a consensus target price of $20.60, suggesting a potential upside of 138.98%. Given Immatics' higher probable upside, analysts plainly believe Immatics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Parabilis Medicines has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Parabilis Medicines' return on equity of 0.00% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Immatics	-495.71%	-47.41%	-39.45%

Summary

Parabilis Medicines and Immatics tied by winning 6 of the 12 factors compared between the two stocks.

How does Immatics compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

64.4% of Immatics shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Edgewise Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Edgewise Therapeutics' score of 0.75 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics currently has a consensus price target of $50.33, suggesting a potential upside of 11.06%. Immatics has a consensus price target of $20.60, suggesting a potential upside of 138.98%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Edgewise Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Edgewise Therapeutics' return on equity of -39.01% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Immatics	-495.71%	-47.41%	-39.45%

Edgewise Therapeutics has higher earnings, but lower revenue than Immatics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A

Summary

Edgewise Therapeutics beats Immatics on 10 of the 16 factors compared between the two stocks.

How does Immatics compare to ACADIA Pharmaceuticals?

Immatics (NASDAQ:IMTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Immatics' net margin of -495.71%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

ACADIA Pharmaceuticals has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29

Immatics currently has a consensus price target of $20.60, suggesting a potential upside of 138.98%. ACADIA Pharmaceuticals has a consensus price target of $34.36, suggesting a potential upside of 25.91%. Given Immatics' higher probable upside, research analysts clearly believe Immatics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

64.4% of Immatics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 1 mentions for Immatics. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Immatics' score of 1.02 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Immatics on 13 of the 16 factors compared between the two stocks.

How does Immatics compare to Celcuity?

Immatics (NASDAQ:IMTX) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Immatics presently has a consensus target price of $20.60, suggesting a potential upside of 138.98%. Celcuity has a consensus target price of $154.75, suggesting a potential upside of 91.97%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Immatics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Immatics' return on equity of -47.41% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Celcuity	N/A	-350.78%	-41.54%

Celcuity has lower revenue, but higher earnings than Immatics. Celcuity is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Celcuity had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Celcuity and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Celcuity's score of 0.83 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

64.4% of Immatics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 3.3% of Immatics shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Immatics beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Immatics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Immatics (NASDAQ:IMTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Enliven Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -495.71%. Enliven Therapeutics' return on equity of -18.55% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Immatics	-495.71%	-47.41%	-39.45%

In the previous week, Enliven Therapeutics had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Enliven Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.02 beat Enliven Therapeutics' score of 0.54 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has higher earnings, but lower revenue than Immatics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Immatics	$54.60M	21.58	-$222.26M	-$1.86	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 3.3% of Immatics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enliven Therapeutics currently has a consensus price target of $75.00, suggesting a potential upside of 51.67%. Immatics has a consensus price target of $20.60, suggesting a potential upside of 138.98%. Given Immatics' higher possible upside, analysts clearly believe Immatics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Enliven Therapeutics beats Immatics on 9 of the 15 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.21B	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-4.63	14.30	275.79	25.40
Price / Sales	21.58	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	2.11	15.45	10.46	6.33
Net Income	-$222.26M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.93%	-1.21%	0.59%	1.12%
1 Month Performance	-6.81%	-4.42%	-2.01%	-2.67%
1 Year Performance	28.66%	37.81%	18.09%	6.01%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	3.2692 of 5 stars	$8.62 -2.3%	$20.60 +139.0%	+30.4%	$1.21B	$54.60M	N/A	704	Positive News
PBLS Parabilis Medicines	1.5724 of 5 stars	$39.77 -1.6%	$41.67 +4.8%	N/A	$4.91B	N/A	N/A	N/A	News Coverage
EWTX Edgewise Therapeutics	2.4456 of 5 stars	$43.82 +1.7%	$50.33 +14.9%	+191.8%	$4.76B	N/A	N/A	60	Positive News Options Volume
ACAD ACADIA Pharmaceuticals	4.436 of 5 stars	$27.58 -1.6%	$34.36 +24.6%	+10.3%	$4.75B	$1.14B	12.42	510
CELC Celcuity	2.9871 of 5 stars	$93.02 -2.8%	$154.55 +66.1%	+46.5%	$4.55B	N/A	N/A	40	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. PBLS, EWTX, ACAD, CELC, and ELVN

How does Immatics compare to Parabilis Medicines?

Summary

How does Immatics compare to Edgewise Therapeutics?

Summary

How does Immatics compare to ACADIA Pharmaceuticals?

Summary

How does Immatics compare to Celcuity?

Summary

How does Immatics compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. PBLS, EWTX, ACAD, CELC, and ELVN

How does Immatics compare to Parabilis Medicines?

Which has stronger earnings & valuation, PBLS or IMTX?

Does the media prefer PBLS or IMTX?

Do analysts recommend PBLS or IMTX?

Do insiders & institutionals hold more shares of PBLS or IMTX?

Is PBLS or IMTX more profitable?

Summary

How does Immatics compare to Edgewise Therapeutics?

Do insiders and institutionals hold more shares of EWTX or IMTX?

Which has more volatility & risk, EWTX or IMTX?

Does the media favor EWTX or IMTX?

Do analysts prefer EWTX or IMTX?

Is EWTX or IMTX more profitable?

Which has higher valuation & earnings, EWTX or IMTX?

Summary

How does Immatics compare to ACADIA Pharmaceuticals?

Which has more risk & volatility, IMTX or ACAD?

Is IMTX or ACAD more profitable?

Which has stronger valuation and earnings, IMTX or ACAD?

Do analysts rate IMTX or ACAD?

Do insiders & institutionals have more ownership in IMTX or ACAD?

Does the media refer more to IMTX or ACAD?

Summary

How does Immatics compare to Celcuity?

Do analysts prefer IMTX or CELC?

Which has more risk and volatility, IMTX or CELC?

Is IMTX or CELC more profitable?

Which has higher earnings and valuation, IMTX or CELC?

Does the media refer more to IMTX or CELC?

Do insiders & institutionals hold more shares of IMTX or CELC?

Summary

How does Immatics compare to Enliven Therapeutics?

Which has more risk and volatility, ELVN or IMTX?

Is ELVN or IMTX more profitable?

Does the media prefer ELVN or IMTX?

Which has better earnings & valuation, ELVN or IMTX?

Do insiders and institutionals have more ownership in ELVN or IMTX?

Do analysts recommend ELVN or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools